Title:
医薬
Document Type and Number:
Japanese Patent JP6467545
Kind Code:
B2
Abstract:
To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
Inventors:
Takashi Oshima
Masatoshi Ito
Chisato Nagai
Masatoshi Ito
Chisato Nagai
Application Number:
JP2018126038A
Publication Date:
February 13, 2019
Filing Date:
July 02, 2018
Export Citation:
Assignee:
Kowa Co., Ltd.
International Classes:
A61K31/423; A61K31/496; A61K31/7048; A61K38/13; A61P1/16; A61P3/06; A61P3/10; A61P9/00; A61P9/10; A61P29/00; A61P43/00
Other References:
Kowa Research Institute, Inc.,Drug-Drug Interaction Study in Healthy Adult Volunteers,ClinicalTrials.govに登録された臨床試験「NCT02275962」,2016年 2月 1日,Study Details欄,[retrieved on 2018.07.17], Retrieved from the Internet:
Kowa Research Institute, Inc.,Drug-Drug Interaction Study in Healthy Adult Volunteers,ClinicalTrials.govに登録された臨床試験「NCT02922465」,2016年12月21日,Study Details欄,[retrieved on 2018.07.17], Retrieved from the Internet:
原島秀吉,新薬剤学,株式会社南江堂,2011年,改訂第3版,p.268-269
Kowa Research Institute, Inc.,Drug-Drug Interaction Study in Healthy Adult Volunteers,ClinicalTrials.govに登録された臨床試験「NCT02922465」,2016年12月21日,Study Details欄,[retrieved on 2018.07.17], Retrieved from the Internet:
原島秀吉,新薬剤学,株式会社南江堂,2011年,改訂第3版,p.268-269
Attorney, Agent or Firm:
Alga Patent Office, a patent business corporation